Request a Demo
844-SOFTVUE
News
Get the Latest News
Delphinus Medical Technologies Awarded Technology Breakthrough From Premier, Inc. West Jefferson Medical Center Joins Growing Group of Imaging Centers Installing SoftVue Breast Ultrasound Tomography Delphinus Announces Installation of Its SoftVue Breast Ultrasound Tomography System at McLeod Regional Medical Center Delphinus Adds Dr. Elise Berman as New Medical Director to Growing Executive Team Delphinus Medical Technologies Hires New Chief Financial Officer, Michael Emery Delphinus Medical Technologies Announces New VP of Engineering
<- Back
Device Indicated for Screening Women with Dense Breasts as Adjunct to Digital Mammography.
NOVI, Michigan – Oct 12, 2021 – Delphinus Medical Technologies, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its SoftVue™ 3D Whole Breast Ultrasound Tomography System (SoftVue™) for use as an adjunct to digital mammography in the screening of asymptomatic women with dense breast tissue. Clinical evidence has demonstrated that SoftVue enhances dense breast screening and identifies up to 20% more cancers with greater accuracy and potentially fewer biopsies than full field digital mammography (FFDM) alone. The SoftVue exam is completed with no compression or radiation, and the PMA indication for use allows SoftVue exams to be performed at the same appointment as screening mammograms, facilitating a streamlined workflow and rapid delivery of results.
“SoftVue plus mammography finds more cancers when screening women with dense breasts. The FDA clearance for same day imaging optimizes workflow while providing unparalleled patient comfort with no compression or radiation, will make patient screening more comprehensive, efficient and effective. It is exciting to have a new cutting-edge technology that detects more cancers and does so with fewer biopsies,” said Dr. Rachel Brem, director for breast imaging at George Washington University Hospital, Washington DC and a member of Delphinus’s board of directors.
SoftVue was developed to address the unmet clinical needs for early breast cancer detection in individuals with dense breast tissue (fibrous tissue that can hide cancerous lesions on mammogram scans) and provides a new annual screening solution for this population. The system identifies more cancers, with fewer callbacks, using a proprietary TriAD™ (Triple Acoustic Detection) technology that effectively characterizes tissue by recording reflection, speed and attenuation of sound waves moving through breast tissue, unlike traditional ultrasound which utilizes only reflection.
During the exam, the patient relaxes on her stomach with her breast submerged in a warm water bath. The breast is comfortably stabilized and centered with a disposable Sequr™ Breast Interface gel pad. Imaging is performed with a proprietary 360-degree ring transducer, scanning each breast from the nipple to the chest wall in an average of three minutes, capturing new images every two millimeters. The captured signals are then analyzed using sophisticated algorithms that provide cross-sectional slices of the entire volume of breast tissue.
“Our SoftVue System delivers a breakthrough in tissue characterization and improves the ability to find cancers in dense breast patients. It will be a game changer that will transform clinical practice with a fundamentally new, and highly impactful approach,” said Mark J. Forchette, president and chief executive officer at Delphinus. “The SoftVue PMA approval opens the door to a technological advance in dense breast screening that will help physicians save lives.”
Mammography alone misses about half the cancers in women with dense breasts. The lower sensitivity of mammography in women with dense breast tissue coupled with their substantially increased risk of breast cancer clearly demonstrates the need for additional screening approaches to detect the mammographically occult cancers. Those with Breast Imaging Reporting and Database System (BI-RADS) density categories c and d have a four-fold increased risk for developing breast cancer. Forty percent of women in the U.S. have dense breast tissue, so that increased risk, combined with decreased sensitivity, creates a significant challenge for this population. It has become such an obvious public health issue that there is now a federal mandate to inform women if they have dense breasts after every mammogram.
Delphinus executed a Prospective Case Collection (PCC) study that served as the image database for the cancer and non-cancer cases that were subsequently used in a series of multi-reader, multi-case (MRMC) studies conducted by the University of Chicago. The PCC initiative began in the summer of 2017 and ultimately enrolled more than 8,500 asymptomatic patients in c or d density categories at 10 leading breast imaging centers around the US. A team of radiologists analyzed more than three million coronal plane images generated by the initiative.
The pivotal MRMC demonstrated that SoftVue detects and distinguishes between normal (BI-RADS 1 and 2) and abnormal (BI-RADS 3 and 4) lesions with an increase in both sensitivity of 20% and specificity of 8%, as compared to FFDM alone. Additionally, 95% of patients surveyed after their SoftVue exam indicated that they would recommend SoftVue to other women.
“With the approval of SoftVue, we now have a critically needed new tool for screening women with dense breasts to enable the earliest possible detection of cancer,” said Dr. Mary Yamashita, lead investigator of the SoftVue PCC clinical trial and Clinical Associate Professor of Radiology at Keck School of Medicine, University of Southern California, Los Angeles. “It’s a great day for all of the patients and their families, clinicians and technologists that worked so hard to make the rigorous study a success. Our collective work may just change dense breast screening forever.”
To learn more about the SoftVue 3D Whole Breast Ultrasound Tomography system, please click here.
About Delphinus Medical Technologies, Inc.
Headquartered in Novi, Mich., Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue™, featuring the first circular array transducer technology. The patented technology is a 3D whole breast ultrasound tomography system that delivers no radiation, requires no compression, and images the entire breast with a single scan.
SoftVue™ has previously received three 510(k)s, and the PMA approval for dense breast screening adjunct to mammography expands the company’s existing platform of approvals to include breast cancer screening in asymptomatic women with dense breast parenchyma after confirmation that the breast density composition is BI-RADS c or d at the time of screening mammography. The device is not intended to be used as a replacement for screening mammography. SoftVue can be used at the same visit as screening mammography, and the SoftVue images are intended to be interpreted with the mammogram results to enhance screening.
Delphinus was founded as a spin out of the Karmanos Cancer Institute in Detroit and is capitalized through principal investments by Arboretum Ventures, Ann Arbor, Mich., Beringea, Farmington Hills, Mich., State of Michigan Retirement System, North Coast Technology Investors, Ann Arbor, Mich., Venture Investors, Madison, Wis., Hopen Life Science Ventures, Grand Rapids, Mich., and Waycross Ventures, Menlo Park, Calif. For more information, visit www.delphinusmt.com.
MEDIA CONTACT:
Sam Choinski
Pazanga Health Communications
(860) 301-5058
schoinski@pazangahealth.com
Delphinus Receives FDA Approval for its SoftVue 3D Whole Breast Ultrasound Tomography System
October 12, 2021
Device Indicated for Screening Women with Dense Breasts as Adjunct to Digital Mammography.NOVI, Michigan – Oct 12, 2021 – Delphinus Medical Technologies, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its SoftVue™ 3D Whole Breast Ultrasound Tomography System (SoftVue™) for use as an adjunct to digital mammography in the screening of asymptomatic women with dense breast tissue. Clinical evidence has demonstrated that SoftVue enhances dense breast screening and identifies up to 20% more cancers with greater accuracy and potentially fewer biopsies than full field digital mammography (FFDM) alone. The SoftVue exam is completed with no compression or radiation, and the PMA indication for use allows SoftVue exams to be performed at the same appointment as screening mammograms, facilitating a streamlined workflow and rapid delivery of results.
“SoftVue plus mammography finds more cancers when screening women with dense breasts. The FDA clearance for same day imaging optimizes workflow while providing unparalleled patient comfort with no compression or radiation, will make patient screening more comprehensive, efficient and effective. It is exciting to have a new cutting-edge technology that detects more cancers and does so with fewer biopsies,” said Dr. Rachel Brem, director for breast imaging at George Washington University Hospital, Washington DC and a member of Delphinus’s board of directors.
SoftVue was developed to address the unmet clinical needs for early breast cancer detection in individuals with dense breast tissue (fibrous tissue that can hide cancerous lesions on mammogram scans) and provides a new annual screening solution for this population. The system identifies more cancers, with fewer callbacks, using a proprietary TriAD™ (Triple Acoustic Detection) technology that effectively characterizes tissue by recording reflection, speed and attenuation of sound waves moving through breast tissue, unlike traditional ultrasound which utilizes only reflection.
During the exam, the patient relaxes on her stomach with her breast submerged in a warm water bath. The breast is comfortably stabilized and centered with a disposable Sequr™ Breast Interface gel pad. Imaging is performed with a proprietary 360-degree ring transducer, scanning each breast from the nipple to the chest wall in an average of three minutes, capturing new images every two millimeters. The captured signals are then analyzed using sophisticated algorithms that provide cross-sectional slices of the entire volume of breast tissue.
“Our SoftVue System delivers a breakthrough in tissue characterization and improves the ability to find cancers in dense breast patients. It will be a game changer that will transform clinical practice with a fundamentally new, and highly impactful approach,” said Mark J. Forchette, president and chief executive officer at Delphinus. “The SoftVue PMA approval opens the door to a technological advance in dense breast screening that will help physicians save lives.”
Mammography alone misses about half the cancers in women with dense breasts. The lower sensitivity of mammography in women with dense breast tissue coupled with their substantially increased risk of breast cancer clearly demonstrates the need for additional screening approaches to detect the mammographically occult cancers. Those with Breast Imaging Reporting and Database System (BI-RADS) density categories c and d have a four-fold increased risk for developing breast cancer. Forty percent of women in the U.S. have dense breast tissue, so that increased risk, combined with decreased sensitivity, creates a significant challenge for this population. It has become such an obvious public health issue that there is now a federal mandate to inform women if they have dense breasts after every mammogram.
Delphinus executed a Prospective Case Collection (PCC) study that served as the image database for the cancer and non-cancer cases that were subsequently used in a series of multi-reader, multi-case (MRMC) studies conducted by the University of Chicago. The PCC initiative began in the summer of 2017 and ultimately enrolled more than 8,500 asymptomatic patients in c or d density categories at 10 leading breast imaging centers around the US. A team of radiologists analyzed more than three million coronal plane images generated by the initiative.
The pivotal MRMC demonstrated that SoftVue detects and distinguishes between normal (BI-RADS 1 and 2) and abnormal (BI-RADS 3 and 4) lesions with an increase in both sensitivity of 20% and specificity of 8%, as compared to FFDM alone. Additionally, 95% of patients surveyed after their SoftVue exam indicated that they would recommend SoftVue to other women.
“With the approval of SoftVue, we now have a critically needed new tool for screening women with dense breasts to enable the earliest possible detection of cancer,” said Dr. Mary Yamashita, lead investigator of the SoftVue PCC clinical trial and Clinical Associate Professor of Radiology at Keck School of Medicine, University of Southern California, Los Angeles. “It’s a great day for all of the patients and their families, clinicians and technologists that worked so hard to make the rigorous study a success. Our collective work may just change dense breast screening forever.”
To learn more about the SoftVue 3D Whole Breast Ultrasound Tomography system, please click here.
About Delphinus Medical Technologies, Inc.
Headquartered in Novi, Mich., Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue™, featuring the first circular array transducer technology. The patented technology is a 3D whole breast ultrasound tomography system that delivers no radiation, requires no compression, and images the entire breast with a single scan.
SoftVue™ has previously received three 510(k)s, and the PMA approval for dense breast screening adjunct to mammography expands the company’s existing platform of approvals to include breast cancer screening in asymptomatic women with dense breast parenchyma after confirmation that the breast density composition is BI-RADS c or d at the time of screening mammography. The device is not intended to be used as a replacement for screening mammography. SoftVue can be used at the same visit as screening mammography, and the SoftVue images are intended to be interpreted with the mammogram results to enhance screening.
Delphinus was founded as a spin out of the Karmanos Cancer Institute in Detroit and is capitalized through principal investments by Arboretum Ventures, Ann Arbor, Mich., Beringea, Farmington Hills, Mich., State of Michigan Retirement System, North Coast Technology Investors, Ann Arbor, Mich., Venture Investors, Madison, Wis., Hopen Life Science Ventures, Grand Rapids, Mich., and Waycross Ventures, Menlo Park, Calif. For more information, visit www.delphinusmt.com.
MEDIA CONTACT:
Sam Choinski
Pazanga Health Communications
(860) 301-5058
schoinski@pazangahealth.com